NEW YORK, August 7, 2026, 06:08 EDT
- Iovance finished Thursday’s session at $6.21, rising 43.1%, then gained a further 0.5% in premarket trade on Friday.
- Second-quarter revenue surpassed the initial consensus estimate by 14.0%. Amtagvi sales exceeded the company’s stated guidance.
- If the second-quarter rate continues, projected 2026 revenue would total $369.4 million, which is close to the upper end of previous guidance.
Iovance Biotherapeutics NASDAQ:IOVA climbed 43.1% on Thursday following a record quarter for sales. The stock ended the session at $6.21, having peaked at $6.39, which marked a 52-week high. Ahead of Friday’s open, the shares last changed hands at $6.24.
Revenue came in at $99.3 million, well above the early analyst projection of $87.1 million. The company posted a per-share loss of $0.11, beating forecasts by two cents.
The clearest indication for investors stemmed from manufacturing performance. Revenue was up by $27.9 million from the prior quarter, while cost of sales increased just $1.1 million.
This indicates that 96.1% of the quarter-over-quarter revenue growth translated into gross profit before accounting for depreciation and amortisation. The figure is based on Iovance’s preliminary financial data. It points to internal manufacturing expenses being distributed over a greater number of patient treatments.
Quarterly results comparison
| Metric | Q2 2026 | Q1 2026 | Q2 2025 | Preliminary Q2 consensus |
|---|---|---|---|---|
| Revenue, $m | 99.31 | 71.43 | 59.95 | 87.12 |
| Gross margin, excluding D&A | 56.1% | 40.5% | 18.5% | — |
| Operating loss, $m | (51.91) | (81.04) | (113.77) | — |
| Net loss, $m | (47.32) | (79.05) | (111.66) | — |
| Loss per share | (0.11) | (0.19) | (0.33) | (0.13) |
First-quarter revenue, expenses and losses were computed by deducting second-quarter results from the company’s reported figures for the first half. Gross margins were determined based on revenue and cost of sales.
Amtagvi brought in approximately $91 million in revenue for the second quarter, surpassing Iovance’s product guidance range of $79 million to $81 million by about $10 million. Proleukin delivered nearly $9 million.
“Second-quarter revenue hit an all-time high of $99.3 million with a gross margin of 56%,” interim Chief Executive Frederick Vogt stated. Vogt added that Iovance is reassessing its annual revenue guidance of $350 million to $370 million. A revised outlook will be provided in the third quarter. IOVANCE Biotherapeutics, Inc.
The current forecast appears cautious at its lower range. Revenue for the first half totaled $170.7 million. Maintaining the pace seen in the second quarter would result in projected full-year sales of $369.4 million.
How revenue guidance is calculated
| Scenario | 2026 revenue, $m | Required H2 revenue, $m | Average Q3–Q4 revenue, $m | Versus Q2 pace |
|---|---|---|---|---|
| Previous guidance — lower bound | 350.0 | 179.3 | 89.6 | 9.8% below |
| Previous guidance — upper bound | 370.0 | 199.3 | 99.6 | 0.3% above |
| Constant Q2 rate | 369.4 | 198.6 | 99.3 | No change |
The flat-rate scenario is an estimate, not an official company outlook. It presumes zero growth or decline each quarter.
Moves in the market were mostly driven by individual company news. The SPDR S&P Biotech ETF (NYSEARCA:XBI) advanced 1.0% on Thursday. The Nasdaq Composite (INDEXNASDAQ:.IXIC) edged down 0.1%.
Thursday market overview
| Security or index | Close | Daily move |
|---|---|---|
| Iovance Biotherapeutics NASDAQ:IOVA | $6.21 | up 43.09% |
| SPDR S&P Biotech ETF (NYSEARCA:XBI) | $154.50 | up 0.97% |
| Nasdaq Composite (INDEXNASDAQ:.IXIC) | 26,348.35 | down 0.06% |
| Iovance performance versus XBI | — | beats by 42.12 percentage points |
Data source: Google Finance closing figures as of August 6.
Commercial expansion continues. Iovance now lists over 95 approved treatment centres throughout the United States, Canada and Australia, and projects the total will rise to at least 110 by year-end. Unaided physician recognition has almost tripled over the past year. Manufacturing turnaround times are holding at 31 days or fewer.
Liquidity has increased, though equity financing is still significant. Iovance closed June holding approximately $304 million in cash, investments, and restricted cash. Management projects this amount will support operations through the second half of 2028.
The company reported operating cash usage of $132.9 million in the first half. Net proceeds from common stock issuance totaled $148.1 million. Weighted-average shares outstanding in the second quarter rose 34.6% year-on-year to 450.2 million.
Analyst targets show significant variation. In a three-month period, Google Finance surveyed four analysts, all of whom issued Buy ratings. The average price target stood at $9.75, suggesting a potential 57% increase from Thursday’s closing price.
Analyst picks
| Analyst and firm | Recommendation | Target | Date | Implied move from $6.21 |
|---|---|---|---|---|
| Etzer Darout, Barclays LON:BARC | Buy, rating unchanged | $13 | Aug. 7 | +109.3% |
| Joseph Pantginis, H.C. Wainwright | Buy, rating reaffirmed | $9 | Aug. 6 | +44.9% |
| Tyler Van Buren, TD Cowen, part of Toronto-Dominion Bank (TSE:TD) | Buy, rating unchanged | $7 | Aug. 6 | +12.7% |
| Salim Syed, Mizuho Securities, part of Mizuho Financial Group (TYO:8411) | Buy, rating maintained | $10 | June 22 | +61.0% |
| David Dai, UBS SWX:UBSG | Hold, rating reaffirmed | $4 | March 5 | -35.6% |
| Andrea Newkirk, Goldman Sachs NYSE:GS | Sell, rating unchanged | $2 | Feb. 5 | -67.8% |
Google Finance provides the recommendations and implied returns shown. Affiliations with TD Cowen and Mizuho are according to company disclosures.
Further catalysts could come from clinical data. Pivotal lung-cancer cohorts are close to finishing enrollment, with a data update anticipated in the fourth quarter. Regulatory filing is targeted for 2027.
Initial sarcoma results indicated a 50% response rate in the first six evaluable patients. The FDA awarded Fast Track status, and more comprehensive findings will be presented at the ESMO meeting from October 23–27. The limited size of the early cohort restricts definitive interpretation.
Risks: Amtagvi accounted for roughly 92% of revenue in the quarter. The yearly outlook is still being assessed and has not been officially increased. Key risks include manufacturing performance, reimbursement, ongoing confirmatory studies and potential additional equity dilution.
Thursday’s results shifted the current valuation discussion. Investors must now consider if the 56% margin can be maintained. For shares to consistently re-rate higher, revenue momentum needs to continue while preventing a resurgence in costs.
Related articles: NASDAQ:IOVA
